nelarabine (Arranon)
Jump to navigation
Jump to search
Introduction
Trademark: Arranon, FDA approved 2005
Indications
* 89% 4 year progression-free survival reported with adjuvant nelarabine + chemotherapy vs 83% with chemotherapy alone[2]
Manufacturer: GSK
More general terms
References
- ↑ Prescriber's Letter 13(2): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220215&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Ingram I. First-Line Nelarabine Prolongs T-Cell ALL Remission. Overall survival of 90% at 4 years is the highest reported yet in these patients. MedPage Today. May 16, 2018 https://www.medpagetoday.com/meetingcoverage/asco/72912
Dunsmore KP et al COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy. American Society of Clinical Oncology (ASCO) 2018; Abstract 10500.